Clinical and Genetic Aspects of Fetuses With Sex-chromosome Disorders
NCT ID: NCT07304193
Last Updated: 2026-01-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ENROLLING_BY_INVITATION
120 participants
OBSERVATIONAL
2024-01-01
2029-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
1. delineate how variations in sex chromosome number affect the epigenetic and genetic mechanisms regulating gene expression in the placenta and in multiple fetal tissues in fetuses with sex chromosome disorders;
2. identify the epigenetic and genetic mechanisms and placental and fetal alterations that underlie the phenotypic manifestations observed in fetuses with sex chromosome disorders.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Clinical and Genetic Aspects in Fetuses and Children With Sex Chromosome Disorders
NCT07341412
Genetics of Differences of Sex Development and Hypospadias
NCT03102554
Endocrine, Metabolic, Cardiovascular and Immunological Aspects of Sex Chromosome Abnormalities in Relation to Genotype
NCT05425953
Phenotypic and Genotypic Characterisation of a Large, Multicentre Italian Cohort of 46, XY DSD Patients
NCT06723938
Sequence Variations of Genes in the Estrogen Pathway and Perinatal Depression
NCT02373709
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Electively aborted fetuses with genetically verified sex chromosome abnormalities
No interventions assigned to this group
Elective aborted health fetuses
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Fetuses with genetically verified sex chromosome disorders
* Gestational age between 11+0 and 22+6 at the time of abortion or at delivery due to intrauterine fetal death
* Written informed consent
* Age ≥18 years
* No known sex chromosome disorder or other genetic disorder in the fetus
* No known fetal malformations
* Fetal growth within the normal range
* Gestational age between 11+0 and 22+6 at the time of abortion
11 Weeks
22 Weeks
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Aarhus
OTHER
Aarhus University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Anne Skakkebæk, MD, PHD
Role: PRINCIPAL_INVESTIGATOR
Aarhus University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Aarhus University Hospital
Aarhus, , Denmark
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
1-10-72-170-23
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.